Developer docs
API playgroundTry for free, no card

Search company profiles

Neobiomics

Full company profile

uuid025v7sz

Namestring
Neobiomics
Legal namestring
Neobiomics AB
Websiteurl
neobiomics.eu
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Neobiomics AB is a Swedish life-science company founded in 2016 and headquartered in Solna (Stockholm), focused exclusively on neonatal nutrition for preterm infants. The company commercializes two clinically formulated products: ProPrems®, a three-strain probiotic dietary supplement (Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, Streptococcus thermophilus TH-4®) launched in 2019 and packaged in single-dose format with a 24-month shelf life; and NeoMega36®, a food for medical purposes launched in 2023 that delivers ARA and DHA in a 2:1 ratio aligned with ESPGHAN recommendations to support visual development in preterm infants. Both products are manufactured under GMP (21 CFR part 111) and HACCP European food law compliance and are notified in multiple European jurisdictions.

The company sells primarily to neonatal intensive care units (NICUs), hospitals, and healthcare professionals (neonatologists, dietitians, midwives) through a hybrid go-to-market combining exclusive regional distribution partnerships (ExCEEd Orphan in CEE, Ewopharma in Switzerland, BIOS Therapeutics in Greece, KH Medicals in Qatar), direct regional field sales in the UK and Italy, and a transactional e-commerce storefront on neobiomics.eu. Pricing is not publicly disclosed; quotes are issued on request for institutional buyers, and revenue is generated through one-time product sales settled via Stripe or PayPal/Braintree. The company claims 170+ collaborating centres and 100+ hospitals across more than 15 countries, with 5,000+ distributed portions of ProPrems® by March 2020.

Neobiomics is affiliated with Karolinska Institutet Innovations AB, founded by a Consultant Neonatologist/Associate Professor (Stefan Johansson) and a veterinary/pharmaceutical medicine doctor (Philipp Novak), and is backed by life-sciences VC HealthCap (investment May 2026, board seat held by Managing Partner Mårten Steen). Following the February 2024 appointment of Emma Höglund, formerly of MSD/Merck & Co, Novartis, and BCB Medical, as CEO, the leadership team has shifted toward commercial scaling, supported by roughly a dozen staff across sales, product management, customer support, and scientific affairs.

Short descriptiontext

Neobiomics is a Swedish life-science company that develops and sells clinically formulated dietary supplements — ProPrems® (probiotic blend) and NeoMega36® (ARA/DHA medical food) — to NICUs and hospitals for preterm infant nutrition across Europe and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preterm infant nutrition, neonatal dietary supplements, probiotic supplements, clinical nutrition products, infant formula manufacturing
Industry3 codes
PRIMARYAFAHAHAC
Special Medical Purpose Infant Formula Manufacturing (FSMP/Medical Nutrition)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYCRADAEAI
Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins)
SECONDARYCRADAEAO
Baby Nutrition for Special Diets (Gluten-Free, Kosher/Halal, Allergen-Controlled)
NAICS code1 code
  • Food Manufacturing311
SIC code1 code
  • Food And Kindred Products2000
Product category
Neonatal Nutrition Supplements
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales - Dietary Supplements
TypeOne Time License
Description

Neobiomics generates revenue through the sale of its proprietary dietary supplement products (ProPrems® and NeoMega36®) directly to hospitals, healthcare facilities, and through distribution partners across Europe. The company uses third-party payment processors (Stripe, PayPal/Braintree) for transaction processing.

neobiomics.eu
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ProPrems®
Description

A high-quality dietary supplement containing a blend of 3 bacterial strains (Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, Streptococcus thermophilus TH-4®) for infants. ProPrems has been collaborating with 170+ centres across Europe since 2019.

neobiomics.eu
+1 more record
Core offering1 text field

Neobiomics develops, manufactures, and sells clinically-formulated dietary supplements specifically designed for preterm infants. The company's core product line comprises ProPrems®, a proprietary 3-strain probiotic blend for gut health support, and NeoMega36®, an ARA/DHA fatty acid food for medical purposes supporting normal vision development. Products are manufactured under GMP and HACCP standards and sold primarily to neonatal intensive care units (NICUs), hospitals, and healthcare professionals across Europe through direct sales and exclusive regional distribution partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100+ hospitals using ProPrems® as of November 2022
+3 more records
Product overview1 text field

Neobiomics is a Swedish dietary supplement company offering two core products for neonatal care. ProPrems® is the foundational product launched in 2019 — a probiotic blend of three bacterial strains for preterm infants. NeoMega36® is a newer product (2023) designed as a food for special medical purposes enriched with ARA and DHA fatty acids for normal vision development in preterm infants. Both products target the neonatal/preterm care market and are distributed through hospital collaborations across Europe.

Product and service2 records
1ProPrems®
CategoryProbiotic dietary supplement for preterm infants
Description

ProPrems® is a high-quality food supplement (probiotic blend) containing three bacterial strains — Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, and Streptococcus thermophilus TH-4® — designed for neonatal care. It is packed in single-dosage format, has a 24-month shelf life, and is manufactured under GMP (21 CFR part 111) and HACCP European food law compliance. It is intended for preterm infants to support gut health and is sold to hospitals, NICUs, and neonatology clinicians across Europe.

2NeoMega36®
CategoryFatty acid food for medical purposes (ARA/DHA) for preterm infants
Description

NeoMega36® is a food for medical purposes (food supplement) enriched with ARA (arachidonic acid) and DHA (docosahexaenoic acid) tailored for preterm infants. It delivers ARA at 100 mg/kg/d and DHA at 50 mg/kg/d in a 2:1 ratio matching breast milk composition, aligned with ESPGHAN recommendations. It is notified in Sweden, Norway, Germany, the Netherlands, Switzerland, Austria, Iceland, Finland, Czech Republic, Slovenia, Slovakia, and Hungary, and supports the normal development of vision function in preterm infants.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-10
Description

Neobiomics and KH Medicals collaborated for the distribution of ProPrems® in Qatar. This partnership extends Neobiomics' presence to the Middle East market.

2BIOS THERAPEUTICS
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-07-21
Description

Exclusive collaboration for the distribution of ProPrems® in Greece. BIOS THERAPEUTICS serves as the exclusive distributor for the Greek market.

neobiomics.eu
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-02-01
Description

First sales of ProPrems® in the Czech Republic and Hungary through ExCEEd Orphan partnership. The partnership expanded to Central and Eastern Europe region.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-05-21
Description

Exclusive cooperation agreement for distribution of ProPrems® in Central and Eastern Europe (initially Czech Republic and Hungary).

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-05-17
Description

Exclusive collaboration for distribution of ProPrems® in Switzerland. Ewopharma AG serves as the exclusive distributor for the Swiss market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Neobiomics is affiliated with Karolinska Institutet Innovations AB, Stockholm. The company was founded based on research from Karolinska Institutet, and co-founder Stefan Johansson holds an Associate Professor position and PhD at Karolinska Institutet.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medical nutrition arm of Nestlé offering preterm and pediatric nutrition products across global markets. Directly comparable category overlap with Neobiomics' neonatal focus, but as a broad incumbent rather than a niche specialist.

TypeOthers
Description

Global bioscience company producing probiotic strains including BB-12, which Neobiomics uses in ProPrems. Functions as a supplier/enabler in the same value chain rather than a competitor, but its probiotic portfolio targets adjacent infant nutrition applications.

TypeBroad incumbent
Description

Long-established infant formula brand (Enfamil) with preterm and specialty pediatric lines. Overlaps with Neobiomics in NICU feeding, but at much larger scale and as part of Reckitt's broader nutrition portfolio.

TypeRegional player
Description

Swedish pediatric and infant nutrition company (part of Hero Group) with a long presence in Nordic hospitals. Comparable in Swedish origin and pediatric nutrition focus, though with broader product breadth and different distribution model.

5BioGaia
TypeDirect peer
Description

Swedish probiotics company with a portfolio of Lactobacillus and Bifidobacterium strains, including pediatric and infant products. Direct overlap with Neobiomics in probiotic supplementation for infants, including shared use of clinically documented strains and similar NICU/neonatology positioning.

TypeEmerging player
Description

US-based specialty nutrition company focused on human milk-based products for premature infants in NICUs. Directly comparable focus on preterm neonatal nutrition, though concentrated in the US market with a different product modality.

TypeBroad incumbent
Description

Global leader in medical nutrition with a dedicated preterm and neonatal nutrition portfolio (e.g., preterm formula and human milk fortifiers). Comparable in serving NICUs with specialized nutrition, but operates at much larger scale and across many therapeutic areas.

TypeBroad incumbent
Description

Major infant nutrition manufacturer with specialty preterm and post-discharge formulas (e.g., Similac NeoSure). Comparable in serving preterm infants with specialized nutrition, but operates as a global incumbent with broad product breadth.

TypeRegional player
Description

European pediatric nutrition company (parent of Semper) offering infant and specialty nutrition. Comparable in serving neonatal and pediatric nutritional needs across European markets, with broader consumer and medical nutrition portfolio.

TypeRegional player
Description

German family-owned infant nutrition company with organic and specialty formula lines including preterm options. Comparable product category and European market overlap, though with broader consumer-grade positioning.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neobiomics

Neonatal Nutrition Supplementsneobiomics.eu

Neobiomics is a Swedish life-science company that develops and sells clinically formulated dietary supplements — ProPrems® (probiotic blend) and NeoMega36® (ARA/DHA medical food) — to NICUs and hospitals for preterm infant nutrition across Europe and the Middle East.

What Neobiomics does

Neobiomics AB is a Swedish life-science company founded in 2016 and headquartered in Solna (Stockholm), focused exclusively on neonatal nutrition for preterm infants. The company commercializes two clinically formulated products: ProPrems®, a three-strain probiotic dietary supplement (Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, Streptococcus thermophilus TH-4®) launched in 2019 and packaged in single-dose format with a 24-month shelf life; and NeoMega36®, a food for medical purposes launched in 2023 that delivers ARA and DHA in a 2:1 ratio aligned with ESPGHAN recommendations to support visual development in preterm infants. Both products are manufactured under GMP (21 CFR part 111) and HACCP European food law compliance and are notified in multiple European jurisdictions.

The company sells primarily to neonatal intensive care units (NICUs), hospitals, and healthcare professionals (neonatologists, dietitians, midwives) through a hybrid go-to-market combining exclusive regional distribution partnerships (ExCEEd Orphan in CEE, Ewopharma in Switzerland, BIOS Therapeutics in Greece, KH Medicals in Qatar), direct regional field sales in the UK and Italy, and a transactional e-commerce storefront on neobiomics.eu. Pricing is not publicly disclosed; quotes are issued on request for institutional buyers, and revenue is generated through one-time product sales settled via Stripe or PayPal/Braintree. The company claims 170+ collaborating centres and 100+ hospitals across more than 15 countries, with 5,000+ distributed portions of ProPrems® by March 2020.

Neobiomics is affiliated with Karolinska Institutet Innovations AB, founded by a Consultant Neonatologist/Associate Professor (Stefan Johansson) and a veterinary/pharmaceutical medicine doctor (Philipp Novak), and is backed by life-sciences VC HealthCap (investment May 2026, board seat held by Managing Partner Mårten Steen). Following the February 2024 appointment of Emma Höglund, formerly of MSD/Merck & Co, Novartis, and BCB Medical, as CEO, the leadership team has shifted toward commercial scaling, supported by roughly a dozen staff across sales, product management, customer support, and scientific affairs.

Neobiomics firmographics

Firmographics
Name
Neobiomics
Legal name
Neobiomics AB
Website
https://neobiomics.eu
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Neobiomics is a Swedish life-science company that develops and sells clinically formulated dietary supplements — ProPrems® (probiotic blend) and NeoMega36® (ARA/DHA medical food) — to NICUs and hospitals for preterm infant nutrition across Europe and the Middle East.
Ownership category
akta.pro rank

Neobiomics industry classification

Industry
Product category
Neonatal Nutrition Supplements
NAICS
Food Manufacturing (311)
SIC
Food And Kindred Products (2000)
akta.pro industry
PRIMARYAFAHAHAC
Special Medical Purpose Infant Formula Manufacturing (FSMP/Medical Nutrition)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYCRADAEAI
Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins)
SECONDARYCRADAEAO
Baby Nutrition for Special Diets (Gluten-Free, Kosher/Halal, Allergen-Controlled)

Keywords

  • Preterm infant nutrition
  • Neonatal dietary supplements
  • Probiotic supplements
  • Clinical nutrition products
  • Infant formula manufacturing

Where Neobiomics is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Neobiomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Product Sales - Dietary Supplements: Neobiomics generates revenue through the sale of its proprietary dietary supplement products (ProPrems® and NeoMega36®) directly to hospitals, healthcare facilities, and through distribution partners across Europe. The company uses third-party payment processors (Stripe, PayPal/Braintree) for transaction processing.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Neobiomics product offering

Product offering

Core offering

Neobiomics develops, manufactures, and sells clinically-formulated dietary supplements specifically designed for preterm infants. The company's core product line comprises ProPrems®, a proprietary 3-strain probiotic blend for gut health support, and NeoMega36®, an ARA/DHA fatty acid food for medical purposes supporting normal vision development. Products are manufactured under GMP and HACCP standards and sold primarily to neonatal intensive care units (NICUs), hospitals, and healthcare professionals across Europe through direct sales and exclusive regional distribution partners.

Product overview

Neobiomics is a Swedish dietary supplement company offering two core products for neonatal care. ProPrems® is the foundational product launched in 2019 — a probiotic blend of three bacterial strains for preterm infants. NeoMega36® is a newer product (2023) designed as a food for special medical purposes enriched with ARA and DHA fatty acids for normal vision development in preterm infants. Both products target the neonatal/preterm care market and are distributed through hospital collaborations across Europe.

Differentiator

Problem solved

Functional benefit

Brands

  • ProPrems®: A high-quality dietary supplement containing a blend of 3 bacterial strains (Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, Streptococcus thermophilus TH-4®) for infants. ProPrems has been collaborating with 170+ centres across Europe since 2019.
  • NeoMega36®

Products and services

  • ProPrems® ProPrems® is a high-quality food supplement (probiotic blend) containing three bacterial strains — Bifidobacterium infantis Bb-02, Bifidobacterium lactis BB-12®, and Streptococcus thermophilus TH-4® — designed for neonatal care. It is packed in single-dosage format, has a 24-month shelf life, and is manufactured under GMP (21 CFR part 111) and HACCP European food law compliance. It is intended for preterm infants to support gut health and is sold to hospitals, NICUs, and neonatology clinicians across Europe.
  • NeoMega36® NeoMega36® is a food for medical purposes (food supplement) enriched with ARA (arachidonic acid) and DHA (docosahexaenoic acid) tailored for preterm infants. It delivers ARA at 100 mg/kg/d and DHA at 50 mg/kg/d in a 2:1 ratio matching breast milk composition, aligned with ESPGHAN recommendations. It is notified in Sweden, Norway, Germany, the Netherlands, Switzerland, Austria, Iceland, Finland, Czech Republic, Slovenia, Slovakia, and Hungary, and supports the normal development of vision function in preterm infants.

Quantifiable outcome

  • 100+ hospitals using ProPrems® as of November 2022
  • +3 more outcomes

Companies that use Neobiomics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Neobiomics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature3 records

Neobiomics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered regional and core.

  • KH MedicalsregionalChannel Partner/ Reseller/ Distributor · 10 October 2023Neobiomics and KH Medicals collaborated for the distribution of ProPrems® in Qatar. This partnership extends Neobiomics' presence to the Middle East market.
  • BIOS THERAPEUTICSregionalChannel Partner/ Reseller/ Distributor · 21 July 2023Exclusive collaboration for the distribution of ProPrems® in Greece. BIOS THERAPEUTICS serves as the exclusive distributor for the Greek market.
  • ExCEEd Orphan s.r.o.regionalChannel Partner/ Reseller/ Distributor · 1 February 2022First sales of ProPrems® in the Czech Republic and Hungary through ExCEEd Orphan partnership. The partnership expanded to Central and Eastern Europe region.
  • ExCEEd Orphan s.r.o.regionalChannel Partner/ Reseller/ Distributor · 21 May 2021Exclusive cooperation agreement for distribution of ProPrems® in Central and Eastern Europe (initially Czech Republic and Hungary).
  • Ewopharma AGregionalChannel Partner/ Reseller/ Distributor · 17 May 2021Exclusive collaboration for distribution of ProPrems® in Switzerland. Ewopharma AG serves as the exclusive distributor for the Swiss market.
  • Karolinska Institutet Innovations ABcoreStrategic or Co-development PartnerNeobiomics is affiliated with Karolinska Institutet Innovations AB, Stockholm. The company was founded based on research from Karolinska Institutet, and co-founder Stefan Johansson holds an Associate Professor position and PhD at Karolinska Institutet.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Neobiomics competitors and assessment

Company assessment

Broad incumbents

  • Nestlé Health Science: Medical nutrition arm of Nestlé offering preterm and pediatric nutrition products across global markets. Directly comparable category overlap with Neobiomics' neonatal focus, but as a broad incumbent rather than a niche specialist.
  • Mead Johnson Nutrition (Reckitt): Long-established infant formula brand (Enfamil) with preterm and specialty pediatric lines. Overlaps with Neobiomics in NICU feeding, but at much larger scale and as part of Reckitt's broader nutrition portfolio.
  • Nutricia (Danone): Global leader in medical nutrition with a dedicated preterm and neonatal nutrition portfolio (e.g., preterm formula and human milk fortifiers). Comparable in serving NICUs with specialized nutrition, but operates at much larger scale and across many therapeutic areas.
  • Abbott Nutrition: Major infant nutrition manufacturer with specialty preterm and post-discharge formulas (e.g., Similac NeoSure). Comparable in serving preterm infants with specialized nutrition, but operates as a global incumbent with broad product breadth.

Others

  • Chr. Hansen: Global bioscience company producing probiotic strains including BB-12, which Neobiomics uses in ProPrems. Functions as a supplier/enabler in the same value chain rather than a competitor, but its probiotic portfolio targets adjacent infant nutrition applications.

Regional players

  • Semper: Swedish pediatric and infant nutrition company (part of Hero Group) with a long presence in Nordic hospitals. Comparable in Swedish origin and pediatric nutrition focus, though with broader product breadth and different distribution model.
  • Hero Nutritional Products: European pediatric nutrition company (parent of Semper) offering infant and specialty nutrition. Comparable in serving neonatal and pediatric nutritional needs across European markets, with broader consumer and medical nutrition portfolio.
  • HiPP: German family-owned infant nutrition company with organic and specialty formula lines including preterm options. Comparable product category and European market overlap, though with broader consumer-grade positioning.

Direct peers

  • BioGaia: Swedish probiotics company with a portfolio of Lactobacillus and Bifidobacterium strains, including pediatric and infant products. Direct overlap with Neobiomics in probiotic supplementation for infants, including shared use of clinically documented strains and similar NICU/neonatology positioning.

Emerging players

  • Prolacta Bioscience: US-based specialty nutrition company focused on human milk-based products for premature infants in NICUs. Directly comparable focus on preterm neonatal nutrition, though concentrated in the US market with a different product modality.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Neobiomics social profiles

Digital presence

Neobiomics compliance and trust

Trust signal

Compliance3 records

Neobiomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neobiomics leadership team

Management profile

Number of profiles

Profiles13 records

Neobiomics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neobiomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neobiomics

What does Neobiomics do?

Neobiomics develops, manufactures, and sells clinically-formulated dietary supplements specifically designed for preterm infants. The company's core product line comprises ProPrems®, a proprietary 3-strain probiotic blend for gut health support, and NeoMega36®, an ARA/DHA fatty acid food for medical purposes supporting normal vision development. Products are manufactured under GMP and HACCP standards and sold primarily to neonatal intensive care units (NICUs), hospitals, and healthcare professionals across Europe through direct sales and exclusive regional distribution partners.

Is Neobiomics a public or private company?

Neobiomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neobiomics founded?

Neobiomics was founded in 2016. It employs 11 to 50 people.

Where is Neobiomics based?

Neobiomics is headquartered in Solna, Sweden, in the Europe region.

How does Neobiomics make money?

One revenue line is on record: product Sales - Dietary Supplements.

Who are Neobiomics's main competitors?

Broad incumbents on record are Nestlé Health Science, Mead Johnson Nutrition (Reckitt), Nutricia (Danone) and Abbott Nutrition. Chr. Hansen is listed as an others. Regional players are Semper, Hero Nutritional Products and HiPP. BioGaia is listed as a direct peer. Prolacta Bioscience is listed as an emerging player.

Does Neobiomics have an API?

No public API is recorded for Neobiomics.

What industry is Neobiomics in?

Neobiomics's product category is Neonatal Nutrition Supplements. Its primary akta.pro industry code is AFAHAHAC, Special Medical Purpose Infant Formula Manufacturing (FSMP/Medical Nutrition), with a secondary code of CRADAEAI, Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins). Its NAICS code is 311 and its SIC code is 2000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals